Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys
- PMID: 20026151
- DOI: 10.1016/j.pnpbp.2009.12.011
Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys
Abstract
L-Dopa treatment, the gold standard therapy for Parkinson's disease, is hampered by motor complications such as dyskinesias. Recently, impairment of striatal Akt/GSK3 signaling was proposed to play a role in the mechanisms implicated in development of L-Dopa-induced dyskinesias in a rodent model of Parkinson's disease. The present experiment investigated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkeys, the effects on Akt/GSK3 of chronic L-Dopa treatment inducing dyskinesias compared to L-Dopa with CI-1041 (NMDA receptor antagonist) or a low dose of cabergoline (dopamine D2 receptor agonist) preventing dyskinesias. The extensive dopamine denervation induced by MPTP was associated with a decrease by about half of phosphorylated Akt(Ser473) levels in posterior caudate nucleus, anterior and posterior putamen; smaller changes were observed for phosphorylated Akt(Thr308) levels that did not reach statistical significance. Dopamine depletion reduced phosphorylated GSK3beta(Ser9) levels, mainly in posterior putamen whereas pGSK3beta(Tyr216) and pGSK3alpha(Ser21) were unchanged. In posterior caudate nucleus, anterior and posterior putamen of dyskinetic L-Dopa-treated MPTP monkeys, pAkt(Ser473) and pGSK3beta(Ser9) were elevated whereas L-Dopa+cabergoline treated MPTP monkeys without dyskinesias had lower values in posterior striatum as vehicle-treated MPTP monkeys. In non-dyskinetic MPTP monkeys treated with L-Dopa+CI-1041, putamen pAkt(Ser473) and pGSK3beta(Ser9) levels remained elevated as in dyskinetic monkeys while in posterior caudate nucleus, these levels were low as vehicle-treated and lower than L-Dopa treated MPTP monkeys. Extent of phosphorylation of Akt and GSK3beta in putamen correlated positively with dyskinesias scores of MPTP monkeys; these correlations were higher with dopaminergic drugs (L-Dopa, cabergoline) suggesting implication of additional mechanisms and/or signaling molecules in the NMDA antagonist antidyskinetic effect. In conclusion, our results showed that in MPTP monkeys, loss of striatal dopamine decreased Akt/GSK3 signaling and that increased phosphorylation of Akt and GSK3beta was associated with L-Dopa-induced dyskinesias.
Copyright 2010 Elsevier Inc. All rights reserved.
Similar articles
-
Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.Neuropharmacology. 2010 Jan;58(1):286-96. doi: 10.1016/j.neuropharm.2009.06.030. Epub 2009 Jul 2. Neuropharmacology. 2010. PMID: 19576910
-
Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias.Neuroscience. 2010 Jun 2;167(4):1160-7. doi: 10.1016/j.neuroscience.2010.03.022. Epub 2010 Mar 18. Neuroscience. 2010. PMID: 20303391
-
Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.Neuropharmacology. 2014 Apr;79:688-706. doi: 10.1016/j.neuropharm.2014.01.014. Epub 2014 Jan 20. Neuropharmacology. 2014. PMID: 24456747
-
[Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].Rev Neurol (Paris). 2000 Mar;156(3):224-35. Rev Neurol (Paris). 2000. PMID: 10740093 Review. French.
-
Oestrogen receptors and signalling pathways: implications for neuroprotective effects of sex steroids in Parkinson's disease.J Neuroendocrinol. 2012 Jan;24(1):48-61. doi: 10.1111/j.1365-2826.2011.02193.x. J Neuroendocrinol. 2012. PMID: 21790809 Review.
Cited by
-
Neuroprotective Effects of Some Nutraceuticals against Manganese-Induced Parkinson's Disease in Rats: Possible Modulatory Effects on TLR4/NLRP3/NF-κB, GSK-3β, Nrf2/HO-1, and Apoptotic Pathways.Pharmaceuticals (Basel). 2022 Dec 14;15(12):1554. doi: 10.3390/ph15121554. Pharmaceuticals (Basel). 2022. PMID: 36559006 Free PMC article.
-
RasGRP1 is a causal factor in the development of l-DOPA-induced dyskinesia in Parkinson's disease.Sci Adv. 2020 May 1;6(18):eaaz7001. doi: 10.1126/sciadv.aaz7001. eCollection 2020 May. Sci Adv. 2020. PMID: 32426479 Free PMC article.
-
Sustained increase of PKA activity in the postcommissural putamen of dyskinetic monkeys.Mol Neurobiol. 2014 Dec;50(3):1131-41. doi: 10.1007/s12035-014-8688-7. Epub 2014 Apr 5. Mol Neurobiol. 2014. PMID: 24705818
-
Osteocalcin Ameliorates Motor Dysfunction in a 6-Hydroxydopamine-Induced Parkinson's Disease Rat Model Through AKT/GSK3β Signaling.Front Mol Neurosci. 2018 Sep 27;11:343. doi: 10.3389/fnmol.2018.00343. eCollection 2018. Front Mol Neurosci. 2018. PMID: 30319352 Free PMC article.
-
Beyond cAMP: The Regulation of Akt and GSK3 by Dopamine Receptors.Front Mol Neurosci. 2011 Nov 1;4:38. doi: 10.3389/fnmol.2011.00038. eCollection 2011. Front Mol Neurosci. 2011. PMID: 22065948 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases